BridgeBio(US:BBIO) ZACKS·2025-10-29 22:16Core Insights - BridgeBio Pharma reported a quarterly loss of $0.95 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.88, marking an earnings surprise of -7.95% [1] - The company generated revenues of $120.7 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 14.44%, compared to revenues of $2.73 million in the same quarter last year [2] - The stock has increased by approximately 135.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.76 on revenues of $134.92 million, and for the current fiscal year, it is -$3.47 on revenues of $467.46 million [7] - The estimate revisions trend for BridgeBio Pharma was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Generic Drugs industry, to which BridgeBio Pharma belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]